CTLs are targeted to kill β cells in patients with type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope

Ania Skowera, … , Bart O. Roep, Mark Peakman

*J Clin Invest.* 2009;119(9):2843-2843. [https://doi.org/10.1172/JCI35449C1](https://doi.org/10.1172/JCI35449C1).

**Corrigendum**

Corrigendum

Reduced levels of neurotransmitter-degrading enzyme PRCP promote obesity

Richard D. Palmiter


Citation for this corrigendum: *J. Clin. Invest.* **119**:2843 (2009). doi:10.1172/JCI40001C1.

The author wishes to correct an inaccuracy in the title of this article.

The corrected title appears below.

Reduced levels of neurotransmitter-degrading enzyme PRCP promote a lean phenotype

The author regrets the error.

Corrigendum

CTLs are targeted to kill β cells in patients with type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope

Ania Skowera, Richard J. Ellis, Ruben Varela-Calviño, Sefina Arif, Guo Cai Huang, Cassie Van-Krinks, Anna Zaremba, Chloe Rackham, Jennifer S. Allen, Timothy I.M. Tree, Min Zhao, Colin M. Dayan, Andrew K. Sewell, Wendy W. Unger, Jan W. Drijfhout, Ferry Ossendorp, Bart O. Roep, and Mark Peakman


During the preparation of the manuscript, Wendy W. Unger’s name was inadvertently presented incorrectly in the author list. The correct author list appears above.

The authors regret the error.